Evidence map›Paper›PMID 33440817›Full record

ArticleInternational journal of environmental research and public health2021

Identification of Risk Factors to Predict the Occurrences of Relapses in Individuals with Schizophrenia Spectrum Disorder in Iran.

Omran Davarinejad, Tahereh Mohammadi Majd, Farzaneh Golmohammadi, Payam Mohammadi, Farnaz Radmehr, Mostafa Alikhani, Tayebeh Motaei, Mehdi Moradinazar, Annette Brühl, Dena Sadeghi Bahmani and 1 more

Abstract read
In one paragraph

Article in International journal of environmental research and public health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Omran DavarinejadSubstance Abuse Prevention Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah 6719851115, Iran.
Tahereh Mohammadi MajdClinical Research Development Center, Imam Khomeini and Mohammad Kermanshahi and Farabi Hospitals, Kermanshah University of Medical Sciences, Kermanshah 6719851451, Iran.
Farzaneh GolmohammadiClinical Research Development Center, Imam Khomeini and Mohammad Kermanshahi and Farabi Hospitals, Kermanshah University of Medical Sciences, Kermanshah 6719851451, Iran.
Payam MohammadiClinical Research Development Center, Imam Khomeini and Mohammad Kermanshahi and Farabi Hospitals, Kermanshah University of Medical Sciences, Kermanshah 6719851451, Iran.
Farnaz RadmehrClinical Research Development Center, Imam Khomeini and Mohammad Kermanshahi and Farabi Hospitals, Kermanshah University of Medical Sciences, Kermanshah 6719851451, Iran.
Mostafa AlikhaniSubstance Abuse Prevention Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah 6719851115, Iran.ORCID 0000-0001-6848-3027
Tayebeh MotaeiClinical Research Development Center, Imam Khomeini and Mohammad Kermanshahi and Farabi Hospitals, Kermanshah University of Medical Sciences, Kermanshah 6719851451, Iran.
Mehdi MoradinazarClinical Research Development Center, Imam Khomeini and Mohammad Kermanshahi and Farabi Hospitals, Kermanshah University of Medical Sciences, Kermanshah 6719851451, Iran.
Annette BrühlCenter for Affective, Stress and Sleep Disorders (ZASS), University of Basel, 4002 Basel, Switzerland.ORCID 0000-0003-4704-4986
Dena Sadeghi BahmaniCenter for Affective, Stress and Sleep Disorders (ZASS), University of Basel, 4002 Basel, Switzerland.ORCID 0000-0002-1301-5522
Serge BrandSubstance Abuse Prevention Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah 6719851115, Iran.ORCID 0000-0003-2175-2765

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Schizophrenia Spectrum Disorder (SSD) is a chronic psychiatric disorder with a modest treatment outcome. In addition, relapses are commonplace. Here, we sought to identify factors that predict relapse latency and frequency. To this end, we retrospectively analyzed data for individuals with SSD. Medical records of 401 individuals with SSD were analyzed (mean age: 25.51 years; 63.6% males) covering a five-year period. Univariate and multivariate Penalized Likelihood Models with Shared Log-Normal Frailty were used to determine the correlation between discharge time and relapse and to identify risk factors. A total of 683 relapses were observed in males, and 422 relapses in females. The Relapse Hazard Ratio (RHR) decreased with age (RHR = 0.99, CI: (0.98-0.998)) and with participants' adherence to pharmacological treatment (HR = 0.71, CI: 0.58-0.86). In contrast, RHR increased with a history of suicide attempts (HR = 1.32, CI: 1.09-1.60), and a gradual compared to a sudden onset of disease (HR = 1.45, CI: 1.02-2.05). Gender was not predictive. Data indicate that preventive and therapeutic interventions may be particularly important for individuals who are younger at disease onset, have a history of suicide attempts, have experienced a gradual onset of disease, and have difficulties adhering to medication.

Indexed as

SchizophreniaAdultFemaleHumansIranMaleRecurrenceRetrospective StudiesRisk Factorspredictionsrelapseschizophrenia spectrum disordertreatment adherence

Identifiers

PMID33440817
PMCPMC7827717

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.